CapsoVision, Inc. (CV) vs Orchestra BioMed Holdings, Inc. (OBIO)
A side-by-side comparison of CapsoVision, Inc. and Orchestra BioMed Holdings, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
CV
CapsoVision, Inc.
$6.50HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
OBIO
Orchestra BioMed Holdings, Inc.
$5.84HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
Total return — CV vs OBIO
growth of $100 · dividends reinvested · last 1yCV +88.3% (+88.3%/yr)OBIO +117.7% (+117.7%/yr)OBIO compounded faster over this window
CV OBIO
CV vs OBIO: by the numbers
- •OBIO is the larger company ($350M vs $325M market cap).
- •Both run net losses; OBIO's is the smaller (-184.60% vs -214.74% net margin).
Metrics side by side
Valuation
| Metric | CV | OBIO |
|---|---|---|
| P/S ratio | 23.38 | 10.94 |
| P/B ratio | 24.67 | 18.10 |
Profitability
| Metric | CV | OBIO |
|---|---|---|
| Gross margin | 50.88% | 99.32% |
| Operating margin | -188.25% | -154.73% |
| Net margin | -214.74% | -184.60% |
| ROE | -226.56% | -200.64% |
| ROIC | -164.32% | -56.73% |
Growth (annualized)
| Metric | CV | OBIO |
|---|---|---|
| Revenue CAGR (5Y) | N/A | 148.45% |
| Total return CAGR (5Y) | N/A | -9.35% |
Go deeper
Dig into the metrics
CapsoVision ROEOrchestra BioMed ROECapsoVision operating marginOrchestra BioMed operating marginCapsoVision revenue growthOrchestra BioMed revenue growthCapsoVision free cash flowOrchestra BioMed free cash flow
CapsoVision & Orchestra BioMed appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.